GOLDMINE研究:磁共振弹性成像评估MASLD的国际前瞻性队列设计
GOLDMINE是一项多中心国际前瞻性队列,计划纳入最多1000例经活检证实或伴肝硬化的MASLD成人,覆盖全纤维化谱。研究采用集中判读的MRI/MRE等影像标志物,每2年重复并随访至10年,以验证其预测疾病进展和肝脏相关临床结局的能力。
要点
- GOLDMINE旨在验证无创影像标志物对MASLD进展和肝脏临床结局的预测价值。
- 纳入活检证实MASLD或MASLD肝硬化成人,覆盖全纤维化谱,多中心国际设计。
- 基线及每2年行MRI/MRE,年度随访至10年,结局由独立中心裁定。
核心结论
- GOLDMINE建立严格表型化的MASLD队列,整合集中组织学、先进MRI标志物、纵向生物样本库和裁定结局,为验证影像和血液预后标志物提供平台。
研究设计与样本
- 研究者发起的多中心国际纵向队列,计划纳入最多1000例经活检证实MASLD或MASLD肝硬化的成人,覆盖全纤维化谱。
- 受试者来自美国15个中心和4个国际中心(日本、新加坡和法国)。
- 基线行临床表型、振动控制瞬时弹性成像和先进MRI(包括质子密度脂肪分数和磁共振弹性成像)。
- MRI和生物样本库每2年重复(第2年和第4年),年度随访至10年。
- 基线肝组织学集中处理、数字化并由单一专家肝病理学家审阅;所有MRI/MRE集中判读。
主要发现
- 预设临床结局包括进展为肝硬化、临床显著门静脉高压、主要不良肝脏相关结局(腹水、肝性脑病、门静脉高压性出血、肝移植/资格)、肝细胞癌、主要不良心血管事件和全因死亡。
- 所有事件由独立中心裁定。
临床怎么用
- 为消化内科医生提供基于影像标志物(尤其是MRE)对MASLD患者进行纵向风险分层的研究框架。
- 强调集中判读病理和影像在确保多中心研究质量中的作用。
局限性
- 本文为研究设计描述,尚未报告影像标志物预测效能的实证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits marked heterogeneity in fibrosis progression and liver-related outcomes. Liver biopsy is not feasible for longitudinal risk stratification at scale, creating a need for validated non-invasive biomarkers, particularly imaging biomarkers, that can predict clinically meaningful disease progression and liver-related outcomes. AIMS: To describe the design and rationale of the GOLDMINE study, established to determine whether non-invasive imaging biomarkers predict MASLD progression and liver-related clinical outcomes. METHODS: GOLDMINE is an investigator-initiated, multi-centre, international longitudinal cohort enrolling up to 1000 adults with either biopsy-proven MASLD or MASLD cirrhosis across the full fibrosis spectrum. Participants are recruited from 15 sites in the US and 4 international sites (Japan, Singapore and France). At baseline, participants undergo clinical phenotyping, vibration-controlled transient elastography, and advanced magnetic resonance imaging (MRI), including proton-density-fat-fraction and magnetic resonance elastography (MRE). MRI (and biospecimen banking) is repeated at 2-year intervals (years 2 and 4), with annual follow-up visits for up to 10 years. Baseline liver histology is centrally processed, digitized and reviewed by a single expert hepatopathologist; all MRI/MREs are centrally interpreted. RESULTS: The prespecified clinical outcomes include progression to cirrhosis, clinically significant portal hypertension, major adverse liver-related outcomes (ascites, hepatic encephalopathy, portal hypertensive bleeding, liver transplantation/qualification), hepatocellular carcinoma, major adverse cardiovascular events, and all-cause mortality, with independent central adjudication of all events. CONCLUSIONS: GOLDMINE establishes a rigorously phenotyped MASLD cohort integrating centralized histology, advanced MRI-based biomarkers, longitudinal biobanking, and adjudicated outcomes, providing a platform to validate imaging and blood-based prognostic biomarkers in MASLD.
引用
- Sharpton S, Díaz LA, Pepin K, et al. Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography (GOLDMINE): A Multi-Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes. Aliment Pharmacol Ther. 2026. PMID: 42017265. doi:10.1111/apt.70696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。